Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Parkinson’s disease pathology breakthrough

Researchers have found that brain cells of people with early Parkinson's disease have damaged powerhouses. In a new study they have identified 10 groups of gene sets related to the energy production problems in the brain cells of these people.

8 Oct 2010

Endocrine Society urges physicians to apply new insights into the role of beta-cells in type 2 diabetes

A new consensus statement published in the September, 2010, issue of The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) finds that the increasing recognition that beta-cell failure occurs much earlier and severely than commonly believed suggests that regular glycemia screening, early identification of patients at metabolic risk and prompt and aggressive intervention deserves greater emphasis.

7 Oct 2010

Podocytes key to development of kidney failure in diabetes

Diabetes is the leading reason for kidney failure in the world, resulting in patients requiring dialysis or kidney transplantation. New research has found a cell in the kidney called the podocyte could be the key to understanding why this happens.

6 Oct 2010

Research on T cell may lead to new treatment options for type 1 diabetes

A research team from the University of British Columbia and the Child & Family Research Institute (CFRI) at BC Children's Hospital has identified the role of a type of T cell in type 1 diabetes that may lead to new treatment options for young patients.

5 Oct 2010

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

4 Oct 2010

IBM employee-wellness program shows some success for kids

Reuters: "In 2008, IBM launched an Internet-based 'children's rebate program' that let employees and their families choose from a selection of goals revolving around healthy eating, group physical activity, reduced 'screen time' and positive parental role-modeling. A $150 check was offered as incentive to complete the 12-week program. … More than 22,000 employees signed on to participate, representing about half of all employees with children covered by IBM's health plan." About 12,000 completed the program and received the rebate.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Saturated fat intake has limited impact on CVD risk: Research

For the past three decades, saturated fat has been considered a major culprit of cardiovascular disease (CVD) and as a result dietary advice persists in recommending reduced consumption of this macronutrient. However, new evidence shows that saturated fat intake has only a very limited impact on CVD risk causing many to rethink the "saturated fat is bad" paradigm.

4 Oct 2010

BCBC awards grant for cell therapy research in type 1 diabetes

Maike Sander, MD, associate professor of pediatrics and cellular & molecular medicine at the University of California, San Diego School of Medicine has been awarded nearly $5 million by the Beta Cell Biology Consortium (BCBC) to lead an interdisciplinary team in cell therapy research for type 1 diabetes.

4 Oct 2010

Look AHEAD intervention program improves risk factors in obese, type 2 diabetic patients

An intensive lifestyle intervention program designed to achieve and maintain weight loss improves diabetes control and cardiovascular disease risk factors in overweight and obese individuals with type 2 diabetes, according to four-year results of the Look AHEAD study, funded by the National Institutes of Health and the Centers for Disease Control and Prevention. The results are published in the Sept. 27, 2010, issue of the Archives of Internal Medicine.

4 Oct 2010

Researchers find link between arterial stiffness and diastolic function

Physicians have identified a risk factor for heart disease in adulthood that can be present in children as young as 10. They're also calling for screening for this risk factor to help motivate children to exercise and lose weight.

4 Oct 2010

Researchers discover new factors that regulate fat formation

By creating a "map" of histone modifications in fat cells, investigators have discovered two new factors that regulate fat formation, a key step on the road to better understanding obesity, diabetes and other metabolic disorders.

1 Oct 2010

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

In a very large cohort of African-American women in the US, the association between the consumption of alcohol, tea, and coffee and the development of type 2 diabetes mellitus (late onset diabetes) was studied for 12 years. Tea and decaffeinated coffee showed no relation with diabetes, but the regular moderate intake of both caffeinated coffee and alcohol appeared to reduce the risk of contracting late onset diabetes significantly.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

Researchers discover genes that influence human height

An international team of researchers, including a number from the University of North Carolina at Chapel Hill schools of medicine and public health, have discovered hundreds of genes that influence human height.

30 Sep 2010

Michigan University researchers receive funds to study breast cancer risk factors

A team of researchers led by a Michigan State University scientist has been awarded $14 million to identify risk factors for breast cancer in young women, focusing on growth, diet, physical activity and body size during a woman's lifetime.

30 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Research: SorCS1 gene is linked to Alzheimer's disease, Type 2 diabetes

A research team led by Mount Sinai School of Medicine has identified the mechanism behind a single gene linked to the causes of both Alzheimer's disease and Type 2 diabetes.

29 Sep 2010

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway.

28 Sep 2010